Aktive Positionen von Andreas Klostermann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
selectION, Inc.
 selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | - | - | |
| Gründer | - | - | |
| The Education Foundation of the Forest Lake Area | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Andreas Klostermann
Ehemalige bekannte Positionen von Andreas Klostermann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
conoGenetix biosciences GmbH
 conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Vorstandsvorsitzender | 01.01.2002 | 01.10.2017 |
| Gründer | 01.01.2002 | 01.10.2017 |
Statistik
International
| Vereinigte Staaten | 3 |
| Deutschland | 2 |
Operativ
| Director/Board Member | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Health Technology |
| The Education Foundation of the Forest Lake Area | |
conoGenetix biosciences GmbH
conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Health Technology |
- Börse
- Insiders
- Andreas Klostermann
- Erfahrung
